Martin Hildebrandt MD

Prof. Dr. Martin Hildebrandt is a hematologist and transfusion specialist. He graduated from the Free University Berlin in 1993 and was board-certified in Internal Medicine (2002), Hematology and Oncology (2008), and Transfusion Medicine (2016). As coordinator and participant of several EC-funded research projects (ACADEMIC GMP, AGORA, BIOHYBRID, TETRA), he contributed to the definition of an academic position in the development of cell-based and gene therapies in Europe. Prof Hildebrandt has been in charge of Academic GMP facilities in Berlin and Hannover, Germany, before taking over the responsibility for establishing TUMCells, the Interdisciplinary Center for Cellular Therapies at TU Munich School of Medicine, where he serves as Executive Director and Qualified Person. His focus of regulatory expertise lies with GCP/GMP, ATMP development, and manufacture. The major area of research of Martin Hildebrandt is T-cell mediated immunomodulation and Transplant optimization.

Prof. Hildebrandt is a member of the working group on blood-associated infections at the German Federal Ministry of Health, Chair of the Ethics Committee of the State of Berlin, advisor to the German Working Group on Chronic Rare Diseases (ACHSE), several academic consortia, and member of the European QP Association, several editorial boards, national and international professional societies.